- Cutaneous polyarteriitis nodosa with Grave's disease and cholestatic liver disease. Vassileva, V.; Varbanova, B. // Pediatric Rheumatology;2011 Supplement, Vol. 9 Issue Suppl 1, p1
An abstract of the conference paper "Cutaneous polyarteriitis nodosa with Grave's disease and cholestatic liver disease," by V. Vassileva and B. Varbanova is presented.
- Abdominal Pain after Taking Ursodiol. Pratt, Daniel S.; Kaplan, Marshall M. // New England Journal of Medicine;5/20/93, Vol. 328 Issue 20, p1502
A letter to the editor about the use of ursodiol to treat chronic cholestatic liver diseases is presented.
- Management of the Pruritus of Cholestasis: Potential Role of Opiate Antagonists. Bergasa, Nora V.; Jones, E. Anthony // American Journal of Gastroenterology;Oct1991, Vol. 86 Issue 10, p1404
Examines the potential role of opiate antagonists in the management of the pruritus of cholestasis. Information on pruritus in patients with cholestatic liver diseases; List of conventional and resourceful treatments; Assessment of pruritus in cholestatic patients.
- Cholestatic Liver Diseases in Adults. McGill, James M.; Kwiatkowski, Ann P. // American Journal of Gastroenterology;May1998, Vol. 93 Issue 5, p684
Cholestatic liver diseases are a diverse group of disorders that are recognized by either increases in laboratory studies or the appearance of jaundice, fatigue, pruritus, and/or complications of cirrhosis. The etiologies for most forms of these diseases are unknown. In this paper, diagnostic...
- Relationship of intestinal microecology with infantile cholestatic liver disease. PANG Xiaoli; WANG Zhaoxia // Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi;Aug2015, Vol. 31 Issue 8, p1221
Intestinal microecology is an important and complex biological system essential to human health. Intestinal microecology and the liver are closely related in anatomical structure and function. Infantile cholestatic liver disease lead to abnormal bile secretion, abnormal excretion, and reduced...
- Itch and liver: management in primary care. Hegade, Vinod S.; Kendrick, Stuart F. W.; Rehman, Jahangir; Jones, David E. J. // British Journal of General Practice;Jun2015, Vol. 65 Issue 635, pe418
The article discusses itch and liver disease management in primary care. Topics discussed include the development of pruritus in any stage of cholestatic liver disease, diagnosis and treatment of cholestatic pruritus, and antipruritic medications recommended by empirical treatment guideline. It...
- Fatigue in cholestatic liver disease--a perplexing symptom. D. Kumar; R.K. Tandon // Postgraduate Medical Journal;Jul2002, Vol. 78 Issue 921, p404
Fatigue is an important symptom and a quality of life determinant in patients with cholestatic liver disease. The pathogenesis of fatigue is obscure, although alterations in central neurotransmission and peripheral muscle dysfunction have been incriminated. No effective treatment is available at...
- Intramuscular Approach to Liver Cholestatic Disease. Dib Jr., Jacobo // American Journal of Gastroenterology;Dec1998, Vol. 93 Issue 12, p2631
Presents a letter to the editor in response to the article "Cholestatic Liver Diseases in Adults," by J. M. McGill and A. P. Kwiatkowski in the 1998 issue.
- Methotrexate. // Reactions Weekly;Jun2015, Vol. 1557 Issue 1, p157
The article presents a case study of a 52-year old male patient who developed hepatic fibrosis and cholestatic liver disease during treatment with methotrexate.
- Lumena Secures $23M to Advance Trials for Liver Disease Drug. KESHAVAN, MEGHANA // San Diego Business Journal;5/20/2013, Vol. 34 Issue 20, p5
The article reports on the $23 million fund secured by the Lumena Pharmaceuticals Inc. which was intended for the development of a drug for cholestatic liver disease treatment.